drugset
drugset / Trial / NCT00555555

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

NCT00555555 ↗

Phase 4 Active not recruiting 15 enrolled Grifols Biologicals, LLC
NaSingle-groupOpen-labelTreatment

Summary

To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.

Timeline

Start
2007-09
Primary completion
2028-12
Completion
2029-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alphanate SD/HT Protein / enzyme biologic 80 iu/kg —

Indications

hereditary von Willebrand disease